Working… Menu

Trial of Antimycobacterial Therapy in Sarcoidosis (CLEAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01074554
Recruitment Status : Completed
First Posted : February 24, 2010
Results First Posted : October 27, 2016
Last Update Posted : December 12, 2016
Information provided by (Responsible Party):
Wonder Drake, Vanderbilt University

Brief Summary:
Growing research from independent laboratories provide an association between mycobacteria and sarcoidosis. More recent immunologic and molecular studies demonstrate immune responses to mycobacteria virulence factors. The purpose of this study is to assess if administration of anti-mycobacterial drug therapy will aid in resolution of cutaneous sarcoidosis lesions.

Condition or disease Intervention/treatment Phase
Sarcoidosis Drug: Antibiotic Regimen Drug: Placebo Regimen Phase 1 Phase 2

Detailed Description:
Independent molecular and immunologic investigations strengthen the association between mycobacterial antigens and sarcoidosis pathogenesis. Molecular analysis of sarcoidosis granulomas reveals the presence of Mycobacterium tuberculosis complex (MTB) DNA and proteins that are significantly absent from granulomatous controls. Mycobacterial DNA has been detected in cutaneous sarcoidosis lesions, in addition to systemic immune responses against mycobacterial antigens. Due to the association between sarcoidosis and mycobacterial antigens, we postulated that broad spectrum antimycobacterial therapy could lead to restoration of T cell function and clinical improvement of chronic cutaneous sarcoidosis lesions. We investigated the safety and efficacy of Concomitant Levofloxacin, Ethambutol, Azithromycin, and Rifampin (CLEAR) therapy among chronic cutaneous sarcoidosis subjects, with change in lesion diameter from baseline to completion of 8 weeks of therapy as the primary endpoint; we assessed for decreases in granuloma burden, if granulomas were evident upon histologic examination. Change in modified Sarcoidosis Activity Severity Index (SASI) was the secondary endpoint.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: Phase I/II Study of the Effects of Antibiotics on Sarcoidosis Pathogenesis
Study Start Date : February 2010
Actual Primary Completion Date : February 2011
Actual Study Completion Date : February 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Antibiotic Regimen

The Antibiotic Regimen consists of Levaquin 750 mg loading on day 1, then 500 mg po QD and Ethambutol 15-25 mg/kg for a maximum of 1200mg QD and Azithromycin 500mg on day 1, then 250 mg po QD and Rifampin 5-10 mg/kg for a maximum of 300mg po QD.

All four drugs are given concomitantly.

Drug: Antibiotic Regimen
Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg QD Azithromycin 500mg on day 1, then 250 mg po QD Rifampin 5-10 mg/kg for a maximum of 300mg po QD All four drugs are given concomitanly
Other Names:
  • Levaquin=Levofloxacin
  • Ethambutol=Myambutol
  • Azithromycin=Zithromax
  • Rifampin=Rifadin

Placebo Comparator: Placebo Regimen
The placebo regimen consists of Lactose tablets, one for each antibiotic with equivalent pills
Drug: Placebo Regimen
lactose control tablets; one for each antibiotic with equivalent pills
Other Name: Lactose control tablets

Primary Outcome Measures :
  1. Change in Lesion Size at the Completion of Antibiotic Therapy, Measured on a Continuous Scale; Change Will be Determined by Change in Diameter of the Lesions [ Time Frame: Baseline to 8 weeks ]
  2. Granuloma Burden [ Time Frame: Baseline to 8 weeks ]
    Number of patients with a decrease in Granuloma Burden (only in those patients having granulomas present at baseline biopsy)

Secondary Outcome Measures :
  1. Change in Modified Sarcoidosis Activity and Severity Index (SASI) at Completion of Therapy. [ Time Frame: Baseline to 8 weeks ]
    Characterization of lesion severity was conducted using Modified Sarcoidosis Activity and Severity Index (SASI), measuring erythema, induration and desquamation. The modification was that the same scale was applied to any part of the body, instead of the face alone. The scale range is 0 (no problem) to 72 (very severe).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with sarcoidosis as defined by the ATS/ERS/WASOG statement on sarcoidosis as defined by the clinical presentation consistent with sarcoidosis, biopsy finding granulomas, and no alternative for the cause of the granulomas, such as tuberculosis
  2. Patients must have chronic cutaneous skin lesions with or without taking chronic therapy (corticosteroids, methotrexate (max 10mg/week), azathioprine, hydroxychloroquine, cyclophosphamide, minocycline, doxycycline and chloroquine), in which the dose has not been altered in the 2 months prior to starting the study.
  3. Subject has a diagnosis of cutaneous sarcoidosis for greater than 6 months with a Sarcoidosis Activity and Severity Index assessment score of at least 4. Diagnosis can be made by either:

    • Skin lesions characteristic of sarcoidosis and a biopsy showing granulomas with no evidence of mycobacteria, fungus, or malignancy.
    • A biopsy that does not show granulomas, but the patient has characteristic skin lesions and history of clinical features suggesting sarcoidosis (previous biopsy revealing noncaseating granuloma, bilateral hilar adenopathy, erythema nodosum, uveitis, raised ACE level, BAL lymphocytosis (CD4:CD8>3.5), panda/lambda sign on gallium scan)
    • Accepted clinical variants include, but are not necessarily limited to the following:

      • lupus pernio
      • nodular
      • subcutaneous
      • annular
      • angiolupoid
      • plaque
      • papular
      • lichenoid
      • psoriasiform
    • For purposes of this study "moderate to severe cutaneous sarcoidosis" is defined as the presence of sarcoidal skin lesions with any of the following features:

      • At least 5 easily visible facial lesions, or
      • Disease which involves > 3% BSA, or
      • Disease which confers functional impairment (e.g. nasal or visual field obstruction), or
      • Disease which confers significant symptoms of itching and/or pain.
  4. If female, subject is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or is using one of the following methods of birth control for the duration of the study and 90 days after study completion:

    • condoms, sponge, foams, jellies, diaphragm, or intrauterine device
    • contraceptives (oral or parenteral) for three months prior to study drug administration
    • a vasectomized sole partner
    • Females of childbearing potential must have a negative serum pregnancy test at screening visit.

Exclusion Criteria:

  1. No consent/inability to obtain consent.
  2. Age less than 18 years of age.
  3. Inability to obtain biopsy or draw blood.
  4. CPK, ALT or AST >5 times upper limit of normal (ULN)
  5. Pregnancy or breast feeding.
  6. Current use of medications metabolized by rifampin (See Appendix).
  7. Allergy to macrolides, quinolones or rifamycins.
  8. Visual Impairment as defined by differentiating colors.
  9. Family or personal history of long QT syndromes.
  10. Patients receiving another interventional investigational drug within the 30 days prior to dosing
  11. Use of any investigational medication within the past 28 days prior to study enrollment.
  12. Subject has been hospitalized for infection or received IV antibiotics within the previous 2 months prior to baseline.
  13. Subject has a history of tuberculosis at anytime or close contact with a person with active tuberculosis within the previous 6 months, or persistent or active infections requiring hospitalization or treatment with IV antibiotics, IV antiretrovirals, or IV antifungals within 30 days of baseline, OR oral antibiotics, antivirals, or antifungals for purpose of treating infection, within 14 days of baseline.
  14. Evidence of other active skin diseases or skin infections during screening that may interfere with evaluation of sarcoidosis.
  15. Subject has an active infection requiring systemic antibiotics at time of screening
  16. Subject has a history of listeriosis, treated or untreated tuberculosis, exposure to individuals with tuberculosis.
  17. Subject has a variant of sarcoidosis that is not amenable to study evaluation, in the absence of chronic indurated lesions, such as:

    • Acute, "benign" sarcoid associated with erythema nodosum
    • Acute iritis
    • Ichthyosiform sarcoidosis
    • Hypo- or hyperpigmented macular sarcoidosis
    • Ulcerative sarcoidosis
    • Erythroderma
    • Alopecia
  18. Patients otherwise unsuitable for participation in the opinion of the investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01074554

Layout table for location information
United States, Tennessee
Vanderbilt University School of Medicine
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Vanderbilt University
Layout table for investigator information
Principal Investigator: Wonder P Drake, MD Vanerbilt University School of Medicine
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Wonder Drake, Associate Professor of Medicine, Vanderbilt University Identifier: NCT01074554    
Other Study ID Numbers: 091103
First Posted: February 24, 2010    Key Record Dates
Results First Posted: October 27, 2016
Last Update Posted: December 12, 2016
Last Verified: September 2016
Keywords provided by Wonder Drake, Vanderbilt University:
cutaneous lesions
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoproliferative Disorders
Lymphatic Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Infective Agents, Urinary
Renal Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Leprostatic Agents
Nucleic Acid Synthesis Inhibitors
Cytochrome P-450 CYP2B6 Inducers
Cytochrome P-450 Enzyme Inducers
Cytochrome P-450 CYP2C8 Inducers
Cytochrome P-450 CYP2C19 Inducers
Cytochrome P-450 CYP2C9 Inducers
Cytochrome P-450 CYP3A Inducers